HighTower Advisors’s Paratek Pharmaceuticals, Inc. PRTK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | – | Sell |
-53,000
| Closed | -$117K | – | 3810 |
|
|
2023
Q2 | $117K | Buy |
53,000
+20,000
| +61% | +$41.5K | ﹤0.01% | 3042 |
|
|
2023
Q1 | $84K | Hold |
33,000
| – | – | ﹤0.01% | 2976 |
|
|
2022
Q4 | $62K | Hold |
33,000
| – | – | ﹤0.01% | 2998 |
|
|
2022
Q3 | $85K | Hold |
33,000
| – | – | ﹤0.01% | 2797 |
|
|
2022
Q2 | $64K | Buy |
33,000
+8,500
| +35% | +$18.5K | ﹤0.01% | 2874 |
|
|
2022
Q1 | $72K | Hold |
24,500
| – | – | ﹤0.01% | 3039 |
|
|
2021
Q4 | $110K | Hold |
24,500
| – | – | ﹤0.01% | 2904 |
|
|
2021
Q3 | $119K | Hold |
24,500
| – | – | ﹤0.01% | 2831 |
|
|
2021
Q2 | $167K | Buy |
24,500
+9,000
| +58% | +$72.8K | ﹤0.01% | 2703 |
|
|
2021
Q1 | $110K | Hold |
15,500
| – | – | ﹤0.01% | 2745 |
|
|
2020
Q4 | $97K | Sell |
15,500
-43
| -0.3% | -$253 | ﹤0.01% | 2353 |
|
|
2020
Q3 | $84K | Hold |
15,543
| – | – | ﹤0.01% | 2255 |
|
|
2020
Q2 | $81K | Hold |
15,543
| – | – | ﹤0.01% | 2154 |
|
|
2020
Q1 | $49K | Buy |
+15,543
| New | +$57.3K | ﹤0.01% | 2014 |
|
|
2013
Q4 | – | Sell |
-1,072
| Closed | -$41K | – | 1620 |
|
|
2013
Q3 | $41K | Sell |
1,072
-162
| -13% | -$5.8K | ﹤0.01% | 1252 |
|
|
2013
Q2 | $45K | Buy |
+1,234
| New | +$52.9K | ﹤0.01% | 1215 |
|
HighTower Advisors's PRTK Position: Q3 2023 in Review
HighTower Advisors sold out of Paratek Pharmaceuticals, Inc. (PRTK) in Q3 2023, closing a stake of 53,000 shares — an estimated $117K sold.
HighTower Advisors first reported a position in PRTK in Q2 2013 and held it in 16 quarters. The position peaked at $167K in Q2 2021. 0 funds tracked by Wall St. Rank hold PRTK as of Q3 2023.
- HighTower Advisors reported no remaining Paratek Pharmaceuticals, Inc. position as of Q3 2023 after selling out during the quarter.
- HighTower Advisors sold 53,000 Paratek Pharmaceuticals, Inc. shares in Q3 2023, an estimated $117K.
- HighTower Advisors first reported a position in Paratek Pharmaceuticals, Inc. in Q2 2013 and held it in 16 quarters.
- HighTower Advisors's Paratek Pharmaceuticals, Inc. position peaked at $167K in Q2 2021.
- 0 funds tracked by Wall St. Rank held Paratek Pharmaceuticals, Inc. as of Q3 2023.
Based on HighTower Advisors's 13F filing for Q3 2023, filed 8 Nov 2023.